Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short-term Investments: 2017-2025

Historic Short-term Investments for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Sep 2025 value amounting to $23,000.

  • Lineage Cell Therapeutics' Short-term Investments fell 99.54% to $23,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $23,000, marking a year-over-year decrease of 99.54%. This contributed to the annual value of $2.0 million for FY2024, which is 3932.00% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Short-term Investments is $23,000, which was up 35.29% from $17,000 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments peaked at $46.5 million during Q4 2022, and registered a low of $17,000 during Q2 2025.
  • Moreover, its 3-year median value for Short-term Investments was $2.0 million (2024), whereas its average is $6.3 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first slumped by 99.89% in 2023, then soared by 3,932.00% in 2024.
  • Lineage Cell Therapeutics' Short-term Investments (Quarterly) stood at $2.6 million in 2021, then soared by 1,678.29% to $46.5 million in 2022, then slumped by 99.89% to $50,000 in 2023, then skyrocketed by 3,932.00% to $2.0 million in 2024, then tumbled by 99.54% to $23,000 in 2025.
  • Its Short-term Investments stands at $23,000 for Q3 2025, versus $17,000 for Q2 2025 and $19,000 for Q1 2025.